Ascendis Pharma A/S - ADR

ASND - Insider Information

Get informed when a big investor buys or sells

Market Cap$16.9B

Close$

Compare to Similar Companies

	P/E Ratio	Dividends	Return on Equity	Price-to-Sales	Debt-to-Equity
Ascendis Pharma A/S - ADR	19	-	58%	15.3	0.3

$315.84

Target Price by Analysts

14.7% upsideAscendis Pharma A/S Target Price Details

$158.03

Current Fair Value

42.6% downside

Overvalued by 42.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap	$16.90 Billion
Enterprise Value	$16.38 Billion
Earnings per Share	$-3.62
Beta	0.4
Outstanding Shares	64,344,993

Return

Return on Equity	58.35%
Return on Assets	36.07%
Return on Invested Capital	11.64%

Valuation & Multiples

P/E Ratio	19.04
PEG	-8.63
Price to Sales	15.3
Price to Book Ratio	11.97
Enterprise Value to Revenue	13.56
Enterprise Value to EBIT	73.68
Enterprise Value to Net Income	18
Total Debt to Enterprise	0.03
Debt to Equity	0.3

Revenue Sources

No data

Last Earnings Call

Report Date

November 12, 2026

EPS

$1.24

Est. $0.89

Revenue

$418.76 M

Est. $409.40 M

Next Earnings Call

Expected Date

February 10, 2027

EPS Estimate

$1.40

Consensus analyst estimate

Revenue Estimate

$502.53 M

Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 1.00, calls and puts are about even.

Put/Call Ratio	1.0000▲ 64.25%
Total Calls	16,400▼ 97.13%
Total Puts	16,400▼ 91.98%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %	5.50%▼ 98.50%
Total Invested	$805.63M▼ 95.49%
Investors Holding	124▼ 210.00%

About Ascendis Pharma A/S

CEO: Jan Moeller Mikkelsen

Ascendis Pharma A/S Insider Information FAQ

Stockcircle tracks 1 top investor with a current 13F position in Ascendis Pharma A/S. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 4 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 5 open-market insider purchases and 2 open-market insider sales for Ascendis Pharma A/S in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.